Blueprint Medicines Stock Forward View - Simple Exponential Smoothing
| BPMCDelisted Stock | USD 129.46 0.11 0.09% |
Blueprint Stock outlook is based on your current time horizon. Investors can use this forecasting interface to forecast Blueprint Medicines stock prices and determine the direction of Blueprint Medicines Corp's future trends based on various well-known forecasting models. We suggest always using this module together with an analysis of Blueprint Medicines' historical fundamentals, such as revenue growth or operating cash flow patterns.
The value of RSI of Blueprint Medicines' share price is above 70 at the present time suggesting that the stock is becoming overbought or overvalued. The idea behind Relative Strength Index (RSI) is that it helps to track how fast people are buying or selling Blueprint, making its price go up or down. Momentum 76
Buy Stretched
Oversold | Overbought |
Using Blueprint Medicines hype-based prediction, you can estimate the value of Blueprint Medicines Corp from the perspective of Blueprint Medicines response to recently generated media hype and the effects of current headlines on its competitors.
The Simple Exponential Smoothing forecasted value of Blueprint Medicines Corp on the next trading day is expected to be 129.46 with a mean absolute deviation of 1.55 and the sum of the absolute errors of 92.77. Blueprint Medicines after-hype prediction price | USD 129.46 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as delisted stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Blueprint |
Blueprint Medicines Additional Predictive Modules
Most predictive techniques to examine Blueprint price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Blueprint using various technical indicators. When you analyze Blueprint charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Blueprint Medicines Simple Exponential Smoothing Price Forecast For the 22nd of February
Given 90 days horizon, the Simple Exponential Smoothing forecasted value of Blueprint Medicines Corp on the next trading day is expected to be 129.46 with a mean absolute deviation of 1.55, mean absolute percentage error of 16.22, and the sum of the absolute errors of 92.77.Please note that although there have been many attempts to predict Blueprint Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Blueprint Medicines' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Blueprint Medicines Stock Forecast Pattern
| Backtest Blueprint Medicines | Blueprint Medicines Price Prediction | Research Analysis |
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Simple Exponential Smoothing forecasting method's relative quality and the estimations of the prediction error of Blueprint Medicines stock data series using in forecasting. Note that when a statistical model is used to represent Blueprint Medicines stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 119.0586 |
| Bias | Arithmetic mean of the errors | -0.7675 |
| MAD | Mean absolute deviation | 1.5462 |
| MAPE | Mean absolute percentage error | 0.0145 |
| SAE | Sum of the absolute errors | 92.77 |
Predictive Modules for Blueprint Medicines
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Blueprint Medicines Corp. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Blueprint Medicines After-Hype Price Density Analysis
As far as predicting the price of Blueprint Medicines at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Blueprint Medicines or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Blueprint Medicines, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Blueprint Medicines Estimiated After-Hype Price Volatility
In the context of predicting Blueprint Medicines' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Blueprint Medicines' historical news coverage. Blueprint Medicines' after-hype downside and upside margins for the prediction period are 129.46 and 129.46, respectively. We have considered Blueprint Medicines' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models compare with traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Blueprint Medicines is very steady at this time. Analysis and calculation of next after-hype price of Blueprint Medicines Corp is based on 3 months time horizon.
Blueprint Medicines Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Blueprint Medicines is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Blueprint Medicines backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Delisted Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Blueprint Medicines, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.00 | 0.00 | 0.00 | 0.00 | 7 Events / Month | 1 Events / Month | In about 7 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
129.46 | 129.46 | 0.00 |
|
Blueprint Medicines Hype Timeline
Blueprint Medicines Corp is currently traded for 129.46. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Blueprint is expected not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is expected to be very small, whereas the daily expected return is currently at 0.0%. %. The volatility of related hype on Blueprint Medicines is about 0.0%, with the expected price after the next announcement by competition of 129.46. About 99.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 2.51. Blueprint Medicines Corp had not issued any dividends in recent years. Given the investment horizon of 90 days the next expected press release will be in about 7 days. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.Blueprint Medicines Related Hype Analysis
Having access to credible news sources related to Blueprint Medicines' direct competition is more important than ever and may enhance your ability to predict Blueprint Medicines' future price movements. Getting to know how Blueprint Medicines' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Blueprint Medicines may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| CERE | Cerevel Therapeutics Holdings | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| IMGN | ImmunoGen | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| ROIV | Roivant Sciences | (0.41) | 8 per month | 1.28 | 0.12 | 5.43 | (2.75) | 24.15 | |
| RXDX | Prometheus Biosciences | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| RETA | Reata Pharmaceuticals | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| ISEE | IVERIC Bio | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SGFY | Signify Health | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| OSH | Oak Street Health | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| RYZB | RayzeBio Common Stock | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| KRTX | Karuna Therapeutics | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Blueprint Medicines Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Blueprint Medicines stock to make a market-neutral strategy. Peer analysis of Blueprint Medicines could also be used in its relative valuation, which is a method of valuing Blueprint Medicines by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Blueprint Medicines Market Strength Events
Market strength indicators help investors to evaluate how Blueprint Medicines stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Blueprint Medicines shares will generate the highest return on investment. By undertsting and applying Blueprint Medicines stock market strength indicators, traders can identify Blueprint Medicines Corp entry and exit signals to maximize returns.
Blueprint Medicines Risk Indicators
The analysis of Blueprint Medicines' basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Blueprint Medicines' investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting blueprint stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 1.86 | |||
| Semi Deviation | 0.6141 | |||
| Standard Deviation | 3.85 | |||
| Variance | 14.85 | |||
| Downside Variance | 1.88 | |||
| Semi Variance | 0.3771 | |||
| Expected Short fall | (2.41) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Blueprint Medicines
The number of cover stories for Blueprint Medicines depends on current market conditions and Blueprint Medicines' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Blueprint Medicines is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Blueprint Medicines' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Blueprint Medicines Short Properties
Blueprint Medicines' future price predictability will typically decrease when Blueprint Medicines' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Blueprint Medicines Corp often depends not only on the future outlook of the potential Blueprint Medicines' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Blueprint Medicines' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 62.9 M | |
| Cash And Short Term Investments | 615.5 M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Other Consideration for investing in Blueprint Stock
If you are still planning to invest in Blueprint Medicines Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Blueprint Medicines' history and understand the potential risks before investing.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |